172 related articles for article (PubMed ID: 31911428)
1. Interactions between Atorvastatin and the Farnesoid X Receptor Impair Insulinotropic Effects of Bile Acids and Modulate Diabetogenic Risk.
Hoffmeister T; Kaiser J; Lüdtke S; Drews G; Düfer M
Mol Pharmacol; 2020 Mar; 97(3):202-211. PubMed ID: 31911428
[TBL] [Abstract][Full Text] [Related]
2. Bile acids acutely stimulate insulin secretion of mouse β-cells via farnesoid X receptor activation and K(ATP) channel inhibition.
Düfer M; Hörth K; Wagner R; Schittenhelm B; Prowald S; Wagner TF; Oberwinkler J; Lukowski R; Gonzalez FJ; Krippeit-Drews P; Drews G
Diabetes; 2012 Jun; 61(6):1479-89. PubMed ID: 22492528
[TBL] [Abstract][Full Text] [Related]
3. Role of FXR in β-cells of lean and obese mice.
Schittenhelm B; Wagner R; Kähny V; Peter A; Krippeit-Drews P; Düfer M; Drews G
Endocrinology; 2015 Apr; 156(4):1263-71. PubMed ID: 25599407
[TBL] [Abstract][Full Text] [Related]
4. Bile acid treatment and FXR agonism lower postprandial lipemia in mice.
Farr S; Stankovic B; Hoffman S; Masoudpoor H; Baker C; Taher J; Dean AE; Anakk S; Adeli K
Am J Physiol Gastrointest Liver Physiol; 2020 Apr; 318(4):G682-G693. PubMed ID: 32003602
[TBL] [Abstract][Full Text] [Related]
5. Atorvastatin protects against liver and vascular damage in a model of diet induced steatohepatitis by resetting FXR and GPBAR1 signaling.
Marchianò S; Biagioli M; Roselli R; Zampella A; Di Giorgio C; Bordoni M; Bellini R; Morretta E; Monti MC; Distrutti E; Fiorucci S
FASEB J; 2022 Jan; 36(1):e22060. PubMed ID: 34862975
[TBL] [Abstract][Full Text] [Related]
6. Roux-en-Y gastric bypass enhances insulin secretion in type 2 diabetes via FXR-mediated TRPA1 expression.
Kong X; Tu Y; Li B; Zhang L; Feng L; Wang L; Zhang L; Zhou H; Hua X; Ma X
Mol Metab; 2019 Nov; 29():1-11. PubMed ID: 31668381
[TBL] [Abstract][Full Text] [Related]
7. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor.
Pineda Torra I; Claudel T; Duval C; Kosykh V; Fruchart JC; Staels B
Mol Endocrinol; 2003 Feb; 17(2):259-72. PubMed ID: 12554753
[TBL] [Abstract][Full Text] [Related]
8. Defective Bile Acid Signaling Promotes Vascular Dysfunction, Supporting a Role for G-Protein Bile Acid Receptor 1/Farnesoid X Receptor Agonism and Statins in the Treatment of Nonalcoholic Fatty Liver Disease.
Marchianò S; Biagioli M; Bordoni M; Morretta E; Di Giorgio C; Vellecco V; Roselli R; Bellini R; Massa C; Cari L; Urbani G; Ricci P; Monti MC; Giordano A; Brancaleone V; Bucci M; Zampella A; Distrutti E; Cieri E; Cirino G; Fiorucci S
J Am Heart Assoc; 2023 Dec; 12(23):e031241. PubMed ID: 37996988
[TBL] [Abstract][Full Text] [Related]
9. Intestine farnesoid X receptor agonist and the gut microbiota activate G-protein bile acid receptor-1 signaling to improve metabolism.
Pathak P; Xie C; Nichols RG; Ferrell JM; Boehme S; Krausz KW; Patterson AD; Gonzalez FJ; Chiang JYL
Hepatology; 2018 Oct; 68(4):1574-1588. PubMed ID: 29486523
[TBL] [Abstract][Full Text] [Related]
10. Effects of essential fatty acid deficiency on enterohepatic circulation of bile salts in mice.
Lukovac S; Los EL; Stellaard F; Rings EH; Verkade HJ
Am J Physiol Gastrointest Liver Physiol; 2009 Sep; 297(3):G520-31. PubMed ID: 19608735
[TBL] [Abstract][Full Text] [Related]
11. Bile Acids Elevated in Chronic Periaortitis Could Activate Farnesoid-X-Receptor to Suppress IL-6 Production by Macrophages.
Cao S; Meng X; Li Y; Sun L; Jiang L; Xuan H; Chen X
Front Immunol; 2021; 12():632864. PubMed ID: 33968024
[TBL] [Abstract][Full Text] [Related]
12. Farnesoid X receptor signaling activates the hepatic X-box binding protein 1 pathway in vitro and in mice.
Liu X; Guo GL; Kong B; Hilburn DB; Hubchak SC; Park S; LeCuyer B; Hsieh A; Wang L; Fang D; Green RM
Hepatology; 2018 Jul; 68(1):304-316. PubMed ID: 29377207
[TBL] [Abstract][Full Text] [Related]
13. Distinct effects of pravastatin, atorvastatin, and simvastatin on insulin secretion from a beta-cell line, MIN6 cells.
Ishikawa M; Okajima F; Inoue N; Motomura K; Kato T; Takahashi A; Oikawa S; Yamada N; Shimano H
J Atheroscler Thromb; 2006 Dec; 13(6):329-35. PubMed ID: 17192698
[TBL] [Abstract][Full Text] [Related]
14. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element.
Claudel T; Sturm E; Duez H; Torra IP; Sirvent A; Kosykh V; Fruchart JC; Dallongeville J; Hum DW; Kuipers F; Staels B
J Clin Invest; 2002 Apr; 109(7):961-71. PubMed ID: 11927623
[TBL] [Abstract][Full Text] [Related]
15. Farnesoid X receptor agonists suppress hepatic apolipoprotein CIII expression.
Claudel T; Inoue Y; Barbier O; Duran-Sandoval D; Kosykh V; Fruchart J; Fruchart JC; Gonzalez FJ; Staels B
Gastroenterology; 2003 Aug; 125(2):544-55. PubMed ID: 12891557
[TBL] [Abstract][Full Text] [Related]
16. The nuclear receptor FXR is expressed in pancreatic beta-cells and protects human islets from lipotoxicity.
Popescu IR; Helleboid-Chapman A; Lucas A; Vandewalle B; Dumont J; Bouchaert E; Derudas B; Kerr-Conte J; Caron S; Pattou F; Staels B
FEBS Lett; 2010 Jul; 584(13):2845-51. PubMed ID: 20447400
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X Receptor (FXR) Interacts with Camp Response Element Binding Protein (CREB) to Modulate Glucagon-Like Peptide-1 (7-36) Amide (GLP-1) Secretion by Intestinal L Cell.
Li P; Zhu L; Yang X; Li W; Sun X; Yi B; Zhu S
Cell Physiol Biochem; 2018; 47(4):1442-1452. PubMed ID: 29940597
[TBL] [Abstract][Full Text] [Related]
18. Microbiota-induced obesity requires farnesoid X receptor.
Parséus A; Sommer N; Sommer F; Caesar R; Molinaro A; Ståhlman M; Greiner TU; Perkins R; Bäckhed F
Gut; 2017 Mar; 66(3):429-437. PubMed ID: 26740296
[TBL] [Abstract][Full Text] [Related]
19. Differential activation of the human farnesoid X receptor depends on the pattern of expressed isoforms and the bile acid pool composition.
Vaquero J; Monte MJ; Dominguez M; Muntané J; Marin JJ
Biochem Pharmacol; 2013 Oct; 86(7):926-39. PubMed ID: 23928191
[TBL] [Abstract][Full Text] [Related]
20. Farnesoid X receptor inhibits glucagon-like peptide-1 production by enteroendocrine L cells.
Trabelsi MS; Daoudi M; Prawitt J; Ducastel S; Touche V; Sayin SI; Perino A; Brighton CA; Sebti Y; Kluza J; Briand O; Dehondt H; Vallez E; Dorchies E; Baud G; Spinelli V; Hennuyer N; Caron S; Bantubungi K; Caiazzo R; Reimann F; Marchetti P; Lefebvre P; Bäckhed F; Gribble FM; Schoonjans K; Pattou F; Tailleux A; Staels B; Lestavel S
Nat Commun; 2015 Jul; 6():7629. PubMed ID: 26134028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
